FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996322545> ?p ?o ?g. }

• W1996322545 abstract "Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.To test whether higher doses (up to 300 mg daily) improve the response to clopidogrel in the setting of loss-of-function CYP2C19 genotypes.ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patients with cardiovascular disease across 32 sites from October 2010 until September 2011.Maintenance doses of clopidogrel for 4 treatment periods, each lasting approximately 14 days, based on genotype. In total, 247 noncarriers of a CYP2C19*2 loss-of-function allele were to receive 75 and 150 mg daily of clopidogrel (2 periods each), whereas 86 carriers (80 heterozygotes, 6 homozygotes) were to receive 75, 150, 225, and 300 mg daily.Platelet function test results (vasodilator-stimulated phosphoprotein [VASP] phosphorylation and VerifyNow P2Y(12) assays) and adverse events.With 75 mg daily, CYP2C19*2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI]: mean, 70.0%; 95% CI, 66.0%-74.0%, vs 57.5%; 95% CI, 55.1%-59.9%, and VerifyNow P2Y(12) reaction units [PRU]: mean, 225.6; 95% CI, 207.7-243.4, vs 163.6; 95% CI, 154.4-173.9; P < .001 for both comparisons). Among CYP2C19*2 heterozygotes, doses up to 300 mg daily significantly reduced platelet reactivity, with VASP PRI decreasing to 48.9% (95% CI, 44.6%-53.2%) and PRU to 127.5 (95% CI, 109.9-145.2) (P < .001 for trend across doses for both). Whereas 52% of CYP2C19*2 heterozygotes were nonresponders (≥230 PRU) with 75 mg of clopidogrel, only 10% were nonresponders with 225 or 300 mg (P < .001 for both). Clopidogrel, 225 mg daily, reduced platelet reactivity in CYP2C19*2 heterozygotes to levels achieved with standard clopidogrel, 75 mg, in noncarriers (mean ratios of platelet reactivity, VASP PRI, 0.92; 90% CI, 0.85-0.99, and PRU, 0.94; 90% CI, 0.84-1.04). In CYP2C19*2 homozygotes, even with 300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95% CI, 44.9%-91.6%) and mean PRU, 287.0 (95% CI, 170.2-403.8).Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition.clinicaltrials.gov Identifier: NCT01235351." @default.
• W1996322545 created "2016-06-24" @default.
• W1996322545 creator A5016322021 @default.
• W1996322545 creator A5028708866 @default.
• W1996322545 creator A5030057930 @default.
• W1996322545 creator A5034207436 @default.
• W1996322545 creator A5036213583 @default.
• W1996322545 creator A5039011294 @default.
• W1996322545 creator A5040418600 @default.
• W1996322545 creator A5048789881 @default.
• W1996322545 creator A5049630475 @default.
• W1996322545 creator A5062053709 @default.
• W1996322545 creator A5064002558 @default.
• W1996322545 creator A5067192657 @default.
• W1996322545 creator A5071612414 @default.
• W1996322545 creator A5079382012 @default.
• W1996322545 creator A5082003758 @default.
• W1996322545 date "2011-11-23" @default.
• W1996322545 modified "2023-10-13" @default.
• W1996322545 title "Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease" @default.
• W1996322545 cites W104398217 @default.
• W1996322545 cites W119348236 @default.
• W1996322545 cites W1409766979 @default.
• W1996322545 cites W1553345686 @default.
• W1996322545 cites W156743206 @default.
• W1996322545 cites W1993518253 @default.
• W1996322545 cites W2001688139 @default.
• W1996322545 cites W2007108997 @default.
• W1996322545 cites W2012343501 @default.
• W1996322545 cites W2021241943 @default.
• W1996322545 cites W2029179690 @default.
• W1996322545 cites W2046551905 @default.
• W1996322545 cites W2047147079 @default.
• W1996322545 cites W2053379248 @default.
• W1996322545 cites W205995199 @default.
• W1996322545 cites W2091264770 @default.
• W1996322545 cites W2098108932 @default.
• W1996322545 cites W2099022345 @default.
• W1996322545 cites W2107797912 @default.
• W1996322545 cites W2128228188 @default.
• W1996322545 cites W2140319544 @default.
• W1996322545 cites W2140501627 @default.
• W1996322545 cites W2140776066 @default.
• W1996322545 cites W2152823642 @default.
• W1996322545 cites W2154940301 @default.
• W1996322545 cites W2157833432 @default.
• W1996322545 cites W2164386459 @default.
• W1996322545 cites W2169387542 @default.
• W1996322545 cites W2171114137 @default.
• W1996322545 cites W2218723321 @default.
• W1996322545 doi "https://doi.org/10.1001/jama.2011.1703" @default.
• W1996322545 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22088980" @default.
• W1996322545 hasPublicationYear "2011" @default.
• W1996322545 type Work @default.
• W1996322545 sameAs 1996322545 @default.
• W1996322545 citedByCount "298" @default.
• W1996322545 countsByYear W19963225452012 @default.
• W1996322545 countsByYear W19963225452013 @default.
• W1996322545 countsByYear W19963225452014 @default.
• W1996322545 countsByYear W19963225452015 @default.
• W1996322545 countsByYear W19963225452016 @default.
• W1996322545 countsByYear W19963225452017 @default.
• W1996322545 countsByYear W19963225452018 @default.
• W1996322545 countsByYear W19963225452019 @default.
• W1996322545 countsByYear W19963225452020 @default.
• W1996322545 countsByYear W19963225452021 @default.
• W1996322545 countsByYear W19963225452022 @default.
• W1996322545 countsByYear W19963225452023 @default.
• W1996322545 crossrefType "journal-article" @default.
• W1996322545 hasAuthorship W1996322545A5016322021 @default.
• W1996322545 hasAuthorship W1996322545A5028708866 @default.
• W1996322545 hasAuthorship W1996322545A5030057930 @default.
• W1996322545 hasAuthorship W1996322545A5034207436 @default.
• W1996322545 hasAuthorship W1996322545A5036213583 @default.
• W1996322545 hasAuthorship W1996322545A5039011294 @default.
• W1996322545 hasAuthorship W1996322545A5040418600 @default.
• W1996322545 hasAuthorship W1996322545A5048789881 @default.
• W1996322545 hasAuthorship W1996322545A5049630475 @default.
• W1996322545 hasAuthorship W1996322545A5062053709 @default.
• W1996322545 hasAuthorship W1996322545A5064002558 @default.
• W1996322545 hasAuthorship W1996322545A5067192657 @default.
• W1996322545 hasAuthorship W1996322545A5071612414 @default.
• W1996322545 hasAuthorship W1996322545A5079382012 @default.
• W1996322545 hasAuthorship W1996322545A5082003758 @default.
• W1996322545 hasBestOaLocation W19963225451 @default.
• W1996322545 hasConcept C104317684 @default.
• W1996322545 hasConcept C126322002 @default.
• W1996322545 hasConcept C135763542 @default.
• W1996322545 hasConcept C140840227 @default.
• W1996322545 hasConcept C185592680 @default.
• W1996322545 hasConcept C2777628954 @default.
• W1996322545 hasConcept C2777849778 @default.
• W1996322545 hasConcept C2778905298 @default.
• W1996322545 hasConcept C526171541 @default.
• W1996322545 hasConcept C55493867 @default.
• W1996322545 hasConcept C62231903 @default.
• W1996322545 hasConcept C71924100 @default.
• W1996322545 hasConcept C89560881 @default.
• W1996322545 hasConcept C90924648 @default.
• W1996322545 hasConcept C98274493 @default.

• next